CUT Protocol
Retatrutide R25 Fast Start Pen
Your first month of structured Retatrutide optimization.
Technical Specifications
Key Attributes
- Triple-receptor mechanism — GLP-1, GIP, and glucagon activation in a single compound
- Precision 0.25 mg per click dosing for careful, guided titration
- Appetite regulation typically established within weeks of initial dosing
- Conservative 25 mg total volume — structured for first-protocol safety
- European-sourced, quality-controlled preparation — delivered to Bangkok and throughout Thailand
Biohackr.Labs provides product education, protocol guidance, and private client support. Information on this website is not medical advice and does not replace consultation with a licensed healthcare professional.
What's Included
Premium hard case.
Everything included.
Every Biohackr.Labs pen ships in our premium white hard case — holographic logo, foam-fitted interior. Inside: the precision pen, ten individually sealed 31G 8mm micro needles, and all documentation needed to begin your protocol correctly.
Precision pen
Pre-filled, batch quality-controlled pen system ready at your confirmed starting dose.
10× 31G micro needles
31G 8mm individually sealed sterile micro needles. Ten included as standard with every pen.
Protocol card
Starting dose, titration schedule, session guidance, and what to expect — specific to your protocol.
Batch QC documentation
Batch reference, preparation date, and compound specification. Not boilerplate — specific to your order.
Storage & handling guide
Temperature requirements, travel guidance, and handling notes with Bangkok climate context.
WhatsApp support access
Direct channel access throughout your protocol for questions, dose adjustments, and guidance.
Cold-Chain Delivery
Professionally packed
for Bangkok logistics.
Every Biohackr.Labs order is individually sealed, temperature-controlled, and dispatched in protective cold-chain packaging engineered to maintain product integrity from preparation to your door.
2–8°C maintained
Insulated inner liner and cold-pack keep the product in range throughout Bangkok transit.
Discreet outer packaging
Plain kraft outer box — no branding, no product name, no external indication of contents.
Tamper-evident sealing
Every product is individually sealed before dispatch. Integrity is visible at handover.
Step 01
Protocol Overview
“Your first month of structured Retatrutide optimization.”
The R25 Fast Start Pen delivers 25 mg of Retatrutide across a 4-week guided onboarding protocol. As the most advanced triple-receptor agonist currently in active research — targeting GLP-1, GIP, and glucagon receptors simultaneously — Retatrutide represents a significant advance beyond earlier GLP-1 compounds. The R25 is specifically designed for clients beginning their first Retatrutide protocol, with a conservative total volume that supports careful titration and response tracking without excess.
Step 02
Mechanism of Action
Retatrutide activates three receptors involved in metabolic regulation: GLP-1 (appetite and insulin response), GIP (nutrient partitioning and fat metabolism), and glucagon (energy expenditure and hepatic glucose output). This triple-receptor activity produces a compounding metabolic effect beyond what single or dual-receptor compounds achieve. At the 0.25 mg per click precision of the R25 pen, clients can titrate carefully from an initial low dose toward their individual response threshold.
Suggested Use
One weekly subcutaneous administration. Begin at 0.25 mg (1 click) in week one. Titrate as guided through private onboarding. Not for use without protocol guidance.
Who This Protocol Is For
Designed for clients beginning their first Retatrutide protocol in Bangkok or Thailand seeking a structured, cautious entry point with close response monitoring. Ideal for those transitioning from lifestyle approaches or earlier GLP-1 compounds.
Storage — Bangkok & Thailand
Store refrigerated between 2–8°C. In Bangkok and Thailand's tropical climate, refrigerated storage is essential. Do not leave in heat, direct sunlight, or unrefrigerated vehicles. Suitable for travel with a cold pack for journeys under 4 hours.
Potential Side Effects
- GI effects (nausea, vomiting, diarrhoea) — most common; dose-dependent and typically improve with careful titration
- Reduced appetite — expected mechanism effect; can be significant at therapeutic doses
- Injection site reactions — transient redness or discomfort at administration site
- Fatigue — reported during dose escalation phases
- Dysesthesia (tingling or altered skin sensation) — observed in approximately 21% of participants at 12 mg in Phase 3 trial data
- Cardiac effects under active investigation in ongoing Phase 3 trials — prior medical suitability review required
Private Access Required
All Biohackr.Labs protocols are guided through private client onboarding. Dosing and administration are confirmed per client before access is granted.
Enquire on WhatsAppThe Compound
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic once-weekly peptide developed by Eli Lilly — the first triple hormone receptor agonist to enter Phase 3 clinical trials. Where semaglutide activates one receptor and tirzepatide activates two, retatrutide simultaneously activates three: GLP-1, GIP, and glucagon. This triple mechanism produces compounding effects on appetite, fat metabolism, and energy expenditure that neither dual nor single agonists can replicate.
By targeting three complementary metabolic pathways at once, retatrutide addresses the biology of excess weight from multiple angles simultaneously. The result is weight loss outcomes that exceed what single or dual agonist compounds can achieve — including outcomes comparable to bariatric surgery in a subset of patients.
Semaglutide
Ozempic / Wegovy
Mechanism
GLP-1 only
Peak weight loss
~13.9%
Tirzepatide
Mounjaro / Zepbound
Mechanism
GLP-1 + GIP
Peak weight loss
~17.8–20.9%
Retatrutide
Pending (LY3437943)
Mechanism
GLP-1 + GIP + Glucagon
Peak weight loss
~25–30.3%
Cross-trial comparisons have inherent limitations. A head-to-head trial would be required for definitive conclusions.
Triple Mechanism
What Each Agonist Does
GLP-1
Glucagon-Like Peptide-1
Role
Appetite and insulin regulation
Slows gastric emptying to reduce caloric intake, suppresses appetite signals in the hypothalamus, and stimulates glucose-dependent insulin secretion. GLP-1 agonism is the foundation of semaglutide and tirzepatide — and the primary mechanism of all incretin-based compounds.
Key Effect
Appetite reduction + insulin sensitivity
Also in: Semaglutide, Tirzepatide
GIP
Glucose-dependent Insulinotropic Polypeptide
Role
Nutrient partitioning and fat cell metabolism
Enhances insulin sensitivity in peripheral tissues, modulates how the body partitions incoming calories between storage and use, and appears to amplify the appetite-suppressing effects of GLP-1 agonism. GIP is the second receptor targeted by tirzepatide — and a key contributor to its weight loss advantage over semaglutide.
Key Effect
Enhanced insulin sensitivity + fat cell regulation
Also in: Tirzepatide
Glucagon
Glucagon Receptor
Role
Energy expenditure and direct liver fat clearance
The critical differentiator. Glucagon receptor activation directly stimulates the liver to burn stored fat (fatty acid oxidation) and suppresses new fat synthesis (de novo lipogenesis). It also increases basal metabolic rate and thermogenesis — meaning the body burns more calories at rest. No approved obesity medication targets this receptor. It is the mechanism responsible for retatrutide's unprecedented liver fat reduction data.
Key Effect
Increased energy expenditure + hepatic fat clearance
Also in: Unique to Retatrutide among approved/late-stage compounds
Beyond Weight Loss
Emerging Benefits From Clinical Data
Clinical trial data surfacing across the TRIUMPH program suggests retatrutide may offer systemic benefits beyond weight management — driven by the glucagon receptor component that neither semaglutide nor tirzepatide possess.
Metabolic Liver Disease (MASLD/MASH)
The glucagon receptor component drives direct hepatic fat oxidation — the liver burns its stored triglycerides. Phase 2a data (Nature Medicine, 2024) showed 86% liver fat reduction and 90% complete resolution, unprecedented for any pharmacological agent. Phase 3 MASLD/MASH-specific trials are underway.
Knee Osteoarthritis
TRIUMPH-4 (Dec 2025) demonstrated substantial reduction in knee pain and improved physical function in patients with obesity and osteoarthritis — the first Phase 3 drug trial to show this combination of weight and pain outcomes simultaneously.
Systemic Inflammation
TRIUMPH-1 investigators noted "clear improvements in assessed cardiometabolic health measures" including inflammatory markers. The triple receptor mechanism appears to address metabolic inflammation through multiple pathways — weight-independent of the pure weight loss effect.
Insulin Resistance
Significant reductions in HOMA-IR (the standard measure of insulin resistance) have been observed across both Phase 2 and Phase 3 data, suggesting potential utility in pre-diabetic and early diabetic metabolic profiles beyond weight alone.
Sleep Apnoea
A dedicated TRIUMPH trial arm is evaluating retatrutide in adults with obesity and moderate-to-severe obstructive sleep apnoea. Results expected 2026. GLP-1 class compounds have shown sleep apnoea benefit proportional to weight loss; the triple mechanism may amplify this further.
Cardiovascular Outcomes
TRIUMPH-3 is studying retatrutide specifically in adults with established cardiovascular disease — one of the highest-risk obesity populations. The SELECT trial established semaglutide reduces major cardiovascular events by ~20%; whether triple agonism improves this further is the core question. Results expected 2026.
All emerging benefit data is from Phase 2 or Phase 3 clinical trial publications and official Eli Lilly announcements. Retatrutide is investigational. Benefits described are not confirmed clinical indications.
Live Research
TRIUMPH Trial Tracker
Last updated
June 2026
Eli Lilly TRIUMPH Phase 3 · 5 trials · 5,800+ participants
25.0% avg weight loss at 80 weeks (12 mg). 30.3% at 104 weeks. 45.3% lost >30% bodyweight.
Results expected Q2–Q3 2026.
Results expected 2026. Will evaluate MACE outcomes with triple agonism.
28.7% avg weight loss at 68 weeks (12 mg). Substantial knee pain reduction.
Phase 2a: 86% liver fat reduction. Phase 3 results expected 2026.
FDA submission anticipated 2026–2027 following full TRIUMPH program readouts. · All data from official Eli Lilly press releases and peer-reviewed publications. Retatrutide is investigational and not approved for clinical use.
Key Statistics
Phase 3 TRIUMPH Data Highlights
30.3%
Average weight loss at 104 weeks
12 mg dose, TRIUMPH-1 — comparable to bariatric surgery outcomes
Eli Lilly, May 2026
45.3%
Patients losing >30% body weight
12 mg dose — a threshold historically achievable only through surgery
TRIUMPH-1, May 2026
70.3 lbs
Average weight lost at 80 weeks
12 mg dose, TRIUMPH-1 — highest weight loss for any non-surgical intervention in Phase 3
Eli Lilly, May 2026
86%
Liver fat reduction at 48 weeks
12 mg dose, Phase 2a liver sub-study — unprecedented for any pharmacological compound
Nature Medicine, 2024
90%
Patients achieving complete liver fat resolution
<5% liver fat — effectively clearing hepatic steatosis in 9 of 10 participants
Nature Medicine, 2024
5,800+
Participants enrolled in TRIUMPH program
Across four global registrational trials — the largest retatrutide trial program to date
Eli Lilly, 2026
Same Collection
Related CUT Protocols
Private Access
Premium imported peptide pens in Bangkok.
Private protocol access · European-sourced · Quality-controlled · Thailand delivery
Enquire About Retatrutide R25 Fast Start Pen